Factor IX Dose Calculator
Factor IX Dose Calculator
Dose factor IX replacement in haemophilia B. The coefficient is not the one used for factor VIII, and it is not the same for plasma-derived and recombinant products — the wrong choice underdoses by half or by a quarter.
Factor IX Dose
Weight × rise ÷ recovery70 kg, baseline 1 IU/dL, target peak 60 IU/dL, plasma-derived product
Formula — and why it is not the factor VIII formula
Plasma-derived or standard half-life recombinant: recovery 1.0, so dose = weight × rise × 1.0
Recombinant factor IX: recovery 0.8 in adults and 0.7 in children under 15, so the multiplier becomes about 1.25 and 1.43
Compare factor VIII, where 1 IU/kg raises the level by 2 IU/dL and the multiplier is 0.5
- 1.0, not 0.5
- the whole point of this page. One IU/kg of factor IX raises the plasma level by about 1 IU/dL, against 2 IU/dL for factor VIII, because factor IX distributes into the extravascular space as well as the plasma. Running the factor VIII arithmetic on a haemophilia B patient gives exactly half the dose needed
- 0.8 and 0.7 for recombinant
- recombinant factor IX has a lower in vivo recovery than plasma-derived. The nonacog alfa product information gives 0.8 ± 0.2 IU/dL per IU/kg in patients of 12 years and above and 0.7 ± 0.3 in children under 12, and WFH quotes 0.8 in adults and 0.7 under 15 years
- extended half-life products
- recovery and dosing interval both differ again, and differ between products. Use the recovery figure in that product's own summary of product characteristics rather than any of the three offered here
- half-life 18 to 24 hours
- roughly twice that of factor VIII, so once-daily dosing usually suffices where factor VIII needs twice-daily. The longer half-life is the one respect in which haemophilia B is easier to treat
Worked example
70 kg, baseline 1 IU/dL, target peak 60 IU/dL, plasma-derived product
Desired rise = 60 − 1 = 59 IU/dL
70 × 59 ÷ 1.0 = 4,130 IU
The same patient on a recombinant product with a recovery of 0.8 needs 70 × 59 ÷ 0.8 = 5,162.5 IU, rounded up to whole vials — a quarter more
A child under 15 on a recombinant product at a recovery of 0.7 needs 70 × 59 ÷ 0.7 = 5,900 IU
Applying the factor VIII arithmetic by mistake — 70 × 59 × 0.5 — would give 2,065 IU, exactly half the dose this patient needs
Recovery, multiplier and half-life by product type
| Product | Recovery (IU/dL per IU/kg) | Multiplier in the dose equation | Half-life |
|---|---|---|---|
| Factor VIII, standard half-life (for comparison) | About 2.0 | × 0.5 | About 12 hours in adults, shorter in young children |
| Factor IX, plasma-derived or standard half-life | About 1.0 | × 1.0 | About 18–24 hours |
| Recombinant factor IX, adult | About 0.8 | × 1.25 | About 18–24 hours |
| Recombinant factor IX, child under 15 | About 0.7 | × 1.43 | About 18–24 hours |
| Extended half-life factor IX | Product-specific — read the SmPC | Product-specific | Substantially longer; varies by product |
WFH peak factor IX levels by type of bleed — haemophilia B
| Bleed or procedure | Higher-dose peak (IU/dL) | Lower-dose peak (IU/dL) |
|---|---|---|
| Joint (haemarthrosis) | 40–60 | 10–20 |
| Superficial muscle | 40–60 | 10–20 |
| Iliopsoas or deep muscle — initial | 60–80 | 15–30 |
| Intracranial — initial | 60–80 | 50–80 |
| Throat or neck — initial | 60–80 | 30–50 |
| Gastrointestinal — initial | 60–80 | 30–50 |
| Renal | 40 | 15–30 |
| Deep laceration | 40 | 15–30 |
One IU per kilogram, not two — and less again if the product is recombinant
Haemophilia B is dosed with the same arithmetic as haemophilia A and a different coefficient, and that difference is the single most important thing on this page. One international unit of factor VIII per kilogram raises the plasma level by about 2 IU/dL, so the factor VIII multiplier is 0.5. One international unit of factor IX per kilogram raises the plasma level by about 1 IU/dL, because factor IX distributes into the extravascular space as well as the plasma, so the multiplier is 1.0. Running the factor VIII equation on a haemophilia B patient gives exactly half the dose required, and a half dose in an intracranial or iliopsoas bleed is not a near miss.
There is a second coefficient underneath the first. Recombinant factor IX has a lower in vivo recovery than plasma-derived factor IX: the nonacog alfa product information gives 0.8 IU/dL per IU/kg in patients of 12 years and above and 0.7 in younger children, and WFH quotes 0.8 in adults and 0.7 under 15 years. Dividing by those recoveries turns the multiplier into about 1.25 and 1.43, so the same target in the same patient needs a quarter to nearly half again as much product depending on what is in the fridge. That is why product type is an input here rather than an assumption. Extended half-life products differ again and must be dosed on their own stated recovery.
What the longer half-life buys is a gentler schedule. Factor IX lasts about 18 to 24 hours against factor VIII's 12, so once-daily dosing usually covers a bleed where factor VIII needs twice daily. The target peaks come from the WFH third edition table and are close to the haemophilia A figures without being identical: 40 to 60 IU/dL for a joint bleed, 60 to 80 for deep muscle, intracranial, throat and neck or gastrointestinal bleeding and for major surgery, 40 for a renal bleed or deep laceration. Most of those entries pair an initial peak with a maintenance phase lasting days to weeks.
Because factor IX doses look large beside factor VIII doses for the same target, a correctly calculated figure can invite a second look and a downward adjustment. Resist that. If the measured level after a dose is well below the calculated one, the explanation is a wrong recovery assumption or an inhibitor, not an excessive dose. Inhibitors are less common in haemophilia B than in haemophilia A but are more often accompanied by anaphylaxis and by nephrotic syndrome during immune tolerance induction, so a poor response belongs with the haemophilia centre rather than with a larger prescription. Every dose here supports a clinician's prescription rather than replacing it, and blood products are given against a clinical indication, not against a number.
Frequently asked questions
How do I calculate a factor IX dose?
Multiply the weight in kilograms by the desired rise in IU/dL and divide by the product's recovery. For a plasma-derived product with a recovery of 1.0, a 70 kg adult needing a 59 IU/dL rise requires 4,130 IU. A recombinant product with a recovery of 0.8 needs about 5,163 IU for the same target.
Why is the factor IX multiplier 1.0 and not 0.5 like factor VIII?
Because 1 IU/kg of factor IX raises the plasma level by about 1 IU/dL, whereas 1 IU/kg of factor VIII raises it by about 2 IU/dL — factor IX also distributes outside the plasma. Using the factor VIII multiplier on a haemophilia B patient gives exactly half the dose needed.
Does recombinant factor IX need a higher dose?
Yes. Its in vivo recovery is lower — about 0.8 IU/dL per IU/kg in adults and 0.7 in children under 15 — so the multiplier becomes roughly 1.25 and 1.43 respectively. That is 25% to 43% more product than a plasma-derived factor IX for the same target level.
What is the half-life of factor IX?
About 18 to 24 hours for plasma-derived and standard half-life recombinant products, roughly twice that of factor VIII. Once-daily dosing usually suffices where factor VIII would need twice daily. Extended half-life products last substantially longer and vary between products.
Can I use this calculator for an extended half-life factor IX?
No. Extended half-life products have their own in vivo recovery figures and their own dosing intervals, and they differ from one another. Use the recovery stated in that product's summary of product characteristics rather than any of the three offered here.
Related calculators
References
- Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158.
- Pfizer. BeneFIX (nonacog alfa) Summary of Product Characteristics. European Medicines Agency; 2024.
- Rayment R, Chalmers E, Forsyth K, et al. Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B. Br J Haematol. 2020;190(5):684–695.
Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.